What is PolyActiva?
PolyActiva is at the forefront of developing biodegradable implants designed to deliver medication over extended periods, aiming to improve patient outcomes for ophthalmic diseases like glaucoma. Their proprietary Prezia Sustained Drug Delivery Technology platform is built upon robust scientific research, enabling precise and controlled release of therapeutic agents. The company recently presented compelling Phase 2 clinical trial data, which demonstrated a significant reduction in intraocular pressure among glaucoma patients, highlighting the efficacy of their innovative approach. PolyActiva's mission is to enhance the quality of life for individuals suffering from chronic eye conditions through effective, long-term treatment solutions.
How much funding has PolyActiva raised?
PolyActiva has raised a total of $36.9M across 3 funding rounds:
Series A
$1.6M
Series B
$9.5M
Series C
$25.8M
Series A (2011): $1.6M, investors not publicly disclosed
Series B (2013): $9.5M led by Medical Research Commercialisation Fund (MRCF)
Series C (2025): $25.8M supported by NRFC and Brandon Capital
Key Investors in PolyActiva
NRFC
The National Reconstruction Fund Corporation (NRFC) is an Australian Government initiative focused on diversifying and transforming the nation's industry and economy through strategic investments in priority sectors, including medical science. They provide finance for high-value projects, supporting Australian companies in enhancing their capabilities.
Brandon Capital
Brandon Capital Partners is a venture capital firm specializing in seed and venture capital investments within the biomedical sector. They focus on life science companies developing innovative medical solutions to improve patient outcomes, providing support from early-stage seed investment through to expansion capital.
Medical Research Commercialisation Fund (MRCF)
The Medical Research Commercialisation Fund (MRCF), operated by Brandon BioCatalyst, is a leading life science investment fund in Australia and New Zealand. It specializes in transforming biomedical research into medical products, partnering with entrepreneurs to create and manage companies focused on enhancing patient outcomes.
What's next for PolyActiva?
The recent major strategic investment, coupled with the substantial total funding of $36.9M, positions PolyActiva for significant growth and market expansion. The promising Phase 2 clinical data provides a strong foundation for advancing their Prezia technology towards commercialization. This capital infusion is expected to accelerate clinical development, potentially supporting Phase 3 trials and regulatory submissions. Furthermore, the backing from entities like the NRFC and Brandon Capital suggests a strategic alignment with national economic priorities and a focus on high-impact medical science, indicating a clear trajectory towards establishing PolyActiva as a leader in the ophthalmic drug delivery market.
See full PolyActiva company page
